Oxford Biomedica PLC Logo

Oxford Biomedica PLC

A CDMO for cell & gene therapy, providing end-to-end viral vector development & manufacturing.

OXB | IL

Overview

Corporate Details

ISIN(s):
GB00BDFBVT43
LEI:
213800S1GVQNXQ15K851
Country:
United Kingdom
Address:
WINDRUSH COURT, OX4 6LT OXFORD
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Oxford Biomedica PLC (OXB) is a global, innovation-led contract development and manufacturing organization (CDMO) specializing in cell and gene therapy. As a pioneer with over 30 years of experience, the company provides end-to-end services for the development and GMP manufacturing of viral vectors, including lentivirus, adeno-associated virus (AAV), and adenovirus. OXB supports pharmaceutical and biotechnology clients, from early-stage development to commercialization, through its global network of facilities in the UK, US, and France. The company leverages proprietary technology platforms, such as its commercially approved LentiVector™ and inAAVate™ systems, to enable the delivery of life-changing therapies.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-01 08:00
Declaration of Voting Results & Voting Rights Announcements
Total Voting Rights
English 11.6 KB
2025-09-23 08:00
Earnings Release
Interim Results for 6 months ended 30 June 2025
English 732.3 KB
2025-08-22 16:36
Director's Dealing
PDMR Dealings
English 29.1 KB
2025-08-21 11:24
Major Shareholding Notification
Holding(s) in Company
English 22.2 KB
2025-08-20 08:00
Declaration of Voting Results & Voting Rights Announcements
Admission of Shares and Total Voting Rights
English 10.9 KB
2025-08-15 14:45
Director's Dealing
PDMR Dealings
English 18.8 KB
2025-08-15 08:05
Share Issue/Capital Change
Results of Placing
English 43.5 KB
2025-08-14 18:02
Share Issue/Capital Change
Proposed Placing of New Ordinary Shares
English 168.6 KB
2025-08-01 08:00
Capital/Financing Update
OXB Secures New Loan Facility with Oaktree
English 16.3 KB
2025-08-01 08:00
Declaration of Voting Results & Voting Rights Announcements
Total Voting Rights
English 10.9 KB
2025-07-28 08:00
Earnings Release
Half Year Trading Update
English 23.8 KB
2025-07-02 08:00
Board/Management Information
Director Declaration
English 9.6 KB
2025-06-23 08:00
M&A Activity
OXB completes acquisition of US subsidiary
English 12.3 KB
2025-06-17 19:00
Director's Dealing
Director/PDMR Shareholding
English 18.8 KB
2025-06-11 08:02
Pre-Annual General Meeting Information
AGM Update
English 12.6 KB

Automate Your Workflow. Get a real-time feed of all Oxford Biomedica PLC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Oxford Biomedica PLC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
2cureX AB Logo
Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.
Sweden 2CUREX
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom 4BB
4SC AG Logo
Developing small-molecule epigenetic drugs for high-need cancer indications.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.
Sweden ABERA
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom ABDX
ABIONYX Pharma Logo
Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.
France ABNX
Abliva Logo
Develops clinical-stage medicines for rare primary mitochondrial diseases to restore cell function.
Sweden ABLI
AB Science Logo
Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.
France AB
Access Bio, Inc. Logo
Develops and manufactures rapid diagnostic tests for infectious diseases for global health.
United States of America 950130
Active Biotech Logo
Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.
Sweden ACTI

Talk to a Data Expert

Have a question? We'll get back to you promptly.